Category Ranking
98%
Total Visits
921
Avg Visit Duration
2 minutes
Citations
20
Article Abstract
Objective: Little is known about the effect of gut microbial and extended-spectrum β-lactamase-producing Enterobacterales (ESBL-E) carriage, particularly in the general population. The aim of this study was to identify microbiota signatures uniquely correlated with ESBL-E carriage.
Methods: We conducted a case-control study among individuals seeking care at the Sexual Health Clinic or Department of Infectious and Tropical Diseases, Saint-Antoine Hospital, Paris, France. Using coarsened exact matching, 176 participants with ESBL-carriage (i.e. cases) were matched 1:1 to those without ESBL-carriage (i.e. controls) based on sexual group, ESBL-E prevalence of countries travelled in <12 months, number of sexual partners in <6 months, geographic origin, and any antibiotic use in <6 months. 16S rRNA gene amplicon sequencing was used to generate differential abundances at the genus level and measures of α- and β-diversity.
Results: Participants were mostly men (83.2%, n = 293/352) and had a median age of 33 years (interquartile range: 27-44). Nine genera were found associated with ESBL-E carriage: Proteus (p < 0.0001), Carnobacterium (p < 0.0001), Enterorhabdus (p 0.0079), Catonella (p 0.017), Dermacoccus (p 0.017), Escherichia/Shigella (p 0.021), Kocuria (p 0.023), Bacillus (p 0.040), and Filifactor (p 0.043); however, differences were no longer significant after Benjamini-Hochberg correction (q > 0.05). There were no differences between those with versus without ESBL-E carriage in measures of α-diversity (Shannon Diversity Index, p 0.49; Simpson Diversity Index, p 0.54; and Chao1 Richness Estimator, p 0.16) or β-diversity (Bray-Curtis dissimilarity index, p 0.42).
Discussion: In this large carefully controlled study, there is lacking evidence that gut microbial composition and diversity is any different between individuals with and without ESBL-E carriage.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1016/j.cmi.2024.03.016 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Genomic insights into multidrug-resistant extraintestinal pathogenic Escherichia coli O4: H12 harboring mcr-5 and blaSHV-12 on conjugative plasmids isolated from chicken meat in Japan.
J Appl Microbiol
September 2025
Laboratory of Food Microbiology and Hygiene, Graduate School of Integrated Sciences for Life, Hiroshima University, 1-4-4 Kagamiyama, Higashihiroshima 739-8528, Japan.
Aims: This study aims to investigate the genomic profile of a multidrug-resistant Escherichia coli strain, 160-11H1, co-carrying an extended-spectrum β-lactamase (ESBL) and the plasmid-mediated mobile colistin resistance gene, mcr-5.
Methods And Results: The entire genome of the strain was sequenced using Illumina MiSeq and Oxford Nanopore platforms, and de novo assembly was performed using Unicycler. The genome size was 5 031,330 bp and comprised 5 140 coding sequences.
Profile of antimicrobial resistance of uropathogens in urinary tract infections: An analysis of 1117 hospitalized patients in Brazil.
IJID Reg
September 2025
Moriah Institute of Science and Education (MISE), Hospital Moriah, São Paulo, Brazil.
Objectives: Urinary tract infections (UTIs) are among the most common infections worldwide, with being the predominant pathogen, particularly, in women. The rise of antimicrobial resistance, especially due to extended-spectrum β-lactamase-producing , has significantly limited treatment options, posing a serious public health concern. Rational antibiotic use and continuous monitoring of resistance patterns are essential to address this challenge.
View Article and Find Full Text PDFVirulence factors and outcomes in bacteremia caused by extended-spectrum β-lactamase-producing uropathogenic Escherichia coli ST131-H30Rx in a Swedish county.
BMC Infect Dis
September 2025
Department of Cell and Molecular Biology, Uppsala University, Uppsala, Sweden.
Background: Escherichia coli ST131 and clade H30Rx are the most prevalent extended-spectrum β-lactamase-producing E. coli (ESBL-EC) causing bacteremia and urinary tract infections globally and in Sweden. Previous studies have linked ST131-H30Rx with septic shock and mortality, as well as prolonged carriage.
View Article and Find Full Text PDFEfficacy and activity of gepotidacin against bacterial uropathogens, including subsets with molecularly characterized resistance mechanisms and genotypes/epidemiological clones, in females with uncomplicated urinary tract infections: results from two global, pivotal, phase 3 trials (EAGLE-2 and EAGLE-3).
Antimicrob Agents Chemother
September 2025
GSK, Collegeville, Pennsylvania, USA.
Gepotidacin, a novel, bactericidal, first-in-class triazaacenaphthylene antibacterial, was noninferior to nitrofurantoin in two pivotal trials (EAGLE-2 and EAGLE-3) in females with uncomplicated urinary tract infections (uUTIs). Using pooled data, gepotidacin activity and clinical efficacy were evaluated for subsets of molecularly characterized isolates in the microbiological Intent-to-Treat population. The subsets of isolates were characterized based on phenotypic/MIC criteria; all microbiological failure isolates were also characterized.
View Article and Find Full Text PDFEfficacy and activity of gepotidacin against bacterial uropathogens, including drug-resistant phenotypes, in females with uncomplicated urinary tract infections: results from two global, pivotal, phase 3 trials (EAGLE-2 and EAGLE-3).
Antimicrob Agents Chemother
September 2025
GSK, London, United Kingdom.
Two recent Phase 3 trials demonstrated the efficacy of gepotidacin compared with nitrofurantoin to treat uncomplicated urinary tract infections (uUTIs) in females. Pretreatment urine specimens were obtained from all participants. Based on pooled trial data (treatment groups combined), central laboratory culture results identified 1,421 (45%) participants with ≥1 baseline qualifying (≥10 CFU/mL) uropathogen (i.
View Article and Find Full Text PDF